Global Veterinary Biologics Market: Reaching US$ 10 Bn in

Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Exhibiting a healthy growth rate, the global veterinary biologics market will register revenues worth around US$ 10 Bn in 2021. The growth is majorly driven by increasing prevalence of preventative farm animal healthcare to ensure better pet health management, and reduce the risk of diseases including, rabies. Rise in pet ownership across the world are further reflecting growth avenues to market players.

“Given the swelling pressure to feed the ever-growing population sustainably, livestock yield, although flourishing, is confronting the hurdles of infectious and parasitic diseases. Advancements in biotechnology and further innovations are assuring better diagnostics and genomics to develop next-gen veterinary biologics to avoid livestock disorders,” underlines FMI report.

To know more about this market, request a sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2288

Key Findings of FMI’s Report on Veterinary Biologics Market

Vaccines continues to stay atop in the prophylactic treatment for better herd immunity.
Monoclonal antibodies (mAb) would be highly preferred for dermal disease treatment in companion animals.
Livestock is likely to be a key revenue generator in veterinary biologics market.
Owing to direct customer contact for bulk orders, veterinary clinics would significantly contribute market value.
Europe continues to offer most lucrative opportunities; East Asia expected to gather pace.

Veterinary Biologics Market – Key Driving Factors

Increasing pet ownership, globally, to boost revenue generation.
Rising preference for prophylactic animal healthcare to offer conducive ground.
Fast regulatory uptake regarding the usage of veterinary biologics.

Veterinary Biologics Market – Key Restraints

Loopholes in epidemiological knowledge are an existing challenge for market players.
Regional disparities in disease patterns to hinder veterinary biologics production.
Inaccuracies in analyzing antigen/immunogenic structures to hamper market progress.
Commodity-cycle-based characteristic of veterinary biologics to deter margin growth.

Explore the complete veterinary biologics report with detailed market segmentation, 130 illustrative figures, and 43 data tables spread across 232 pages on https://www.futuremarketinsights.com/askus/rep-gb-2288

VETERINARY BIOLOGICS MARKET TAXONOMY

The global veterinary biologics is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product

Vaccines
Attenuated Live Vaccines
Conjugate Vaccines
Inactivated Vaccines
Subunit Vaccines
Toxoid Vaccines
DNA Vaccines
Recombinant Vaccines
Bacterial Extracts
Monoclonal Antibodies
Immunomodulators
- Cytokines
- Others
Allergenic Extracts

Animal Type

Companion Animals
Canine
Avian
Feline
Livestock
- Aquatic
- Bovine
- Porcine
- Ovine/Caprine
- Poultry
Equine

Distribution Channel

Veterinary Clinics
Veterinary Hospitals
Veterinary Research Institutes
Retail Pharmacies

Region

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Asia (MEA)

Competition Landscape of Veterinary Biologics Market

Players in the veterinary biologics market are entering into mergers & acquisitions with small- and medium-scale enterprises (SME) in a bid to optimize their offerings with diverse product portfolio. Key players in the veterinary biologics market include Zoetis Inc., Boehringer Ingelheim, Ceva, Elanco Animal Health, Merck Animal Health, Phibro Animal Health Corporation, Virbac, Hester Biosciences Limited, Colorado Serum Company, Addison Biological Laboratory Inc., American Animal Health Inc., HIPRA, and Bimeda Inc. (Texas Vet Lab Inc.).

Explore Extensive Coverage of FMI’s Healthcare, Pharmaceuticals and Medical Devices Landscape

Companion Animal Vaccines Market – This report provides distinct actionable insights on companion animal vaccines market, offering historical and forecast growth on the basis of various segments.

Companion Animal Speciality Drugs Market – The companion animal specialty drugs market study underlines major influencing factors, and extensive evaluation across key regions.

Companion Animal Drug Market – The comprehensive research study on companion animal drug market assesses recent industry trends in every sub-segment as well as projected value growth at global, regional, and country levels.

About the Report

This FMI report covers the ongoing industry trends and an extensive analysis on veterinary biologics market growth at global, regional, and country levels. The report offers compelling insights based on product (vaccines, bacterial extracts, monoclonal antibodies, immunomodulators, and allergenic extracts), animal type (companion animals, canine, avian, feline, livestock, and equine), distribution channel (veterinary clinics, veterinary hospitals, veterinary research institutes, and retail pharmacies), and across seven key regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa).

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact

Mr. Abhishek Budholiya

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

Market Report: https://www.futuremarketinsights.com/reports/veterinary-biologics-market

Press Release Source: https://www.futuremarketinsights.com/press-release/veterinary-biologics-market